MarketPR
The side-effect profile of existing weight-loss drugs is now the stated target for pharma groups developing the next generation of GLP-1 medicines.
The effort arrives as some patents on current treatments are starting to expire, giving the push commercial weight alongside whatever scientific merit the reformulations eventually carry.
GLP-1 drugs, named for the glucagon-like peptide-1 hormone they work through, built their category on efficacy. The side effects were never part of the sales pitch; they arrived anyway.
A next-generation product that preserves the weight-loss mechanism and reduces what patients have to tolerate on the way would be a distinct offering from the existing class, and a harder one to undercut with generic entry once patent protection fades.
Keep reading